Maya Koren‐Michowitz

5.2k total citations · 2 hit papers
76 papers, 2.9k citations indexed

About

Maya Koren‐Michowitz is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Maya Koren‐Michowitz has authored 76 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 30 papers in Genetics and 20 papers in Molecular Biology. Recurrent topics in Maya Koren‐Michowitz's work include Chronic Myeloid Leukemia Treatments (23 papers), Acute Myeloid Leukemia Research (19 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers). Maya Koren‐Michowitz is often cited by papers focused on Chronic Myeloid Leukemia Treatments (23 papers), Acute Myeloid Leukemia Research (19 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers). Maya Koren‐Michowitz collaborates with scholars based in Israel, United States and Germany. Maya Koren‐Michowitz's co-authors include Arnon Nagler, Batia Avni, Avichai Shimoni, Merav Leiba, Ninette Amariglio, Raanan Berger, Abraham Kneller, Rinat Rotem‐Yehudar, Gideon Rechavi and Yoram Cohen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Maya Koren‐Michowitz

74 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient

2009 684 citations Ninette Amariglio, Luba Trakhtenbrot et al. profile →
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

2008 536 citations Merav Leiba, Maya Koren‐Michowitz et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maya Koren‐Michowitz Israel	22	859	791	749	611	593	76	2.9k
Harshal Nandurkar Australia	33	982 1.1×	463 0.6×	558 0.7×	359 0.6×	721 1.2×	118	3.6k
Jedrzej Hoffmann Germany	26	643 0.7×	251 0.3×	544 0.7×	434 0.7×	462 0.8×	51	3.3k
Margherita Massa Italy	34	1.4k 1.6×	431 0.5×	1.2k 1.7×	876 1.4×	884 1.5×	102	3.6k
Tobias Wirenfeldt Klausen Denmark	32	665 0.8×	1.0k 1.3×	1.1k 1.4×	436 0.7×	492 0.8×	143	3.3k
Dennis A. Gastineau United States	25	670 0.8×	546 0.7×	963 1.3×	411 0.7×	376 0.6×	64	2.4k
Murat O. Arcasoy United States	30	711 0.8×	629 0.8×	1.7k 2.3×	712 1.2×	161 0.3×	58	2.9k
Dávid Ma Australia	21	472 0.5×	1.2k 1.5×	585 0.8×	603 1.0×	293 0.5×	69	2.9k
E. Martín‐Mola Spain	44	409 0.5×	413 0.5×	1.5k 2.0×	663 1.1×	1.6k 2.6×	113	6.0k
Andrea Marzullo Italy	26	910 1.1×	433 0.5×	248 0.3×	248 0.4×	643 1.1×	172	2.7k
Liton Francisco United States	34	529 0.6×	1.1k 1.3×	1.7k 2.3×	301 0.5×	226 0.4×	109	3.9k

Countries citing papers authored by Maya Koren‐Michowitz

Since Specialization

Citations

This map shows the geographic impact of Maya Koren‐Michowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maya Koren‐Michowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maya Koren‐Michowitz more than expected).

Fields of papers citing papers by Maya Koren‐Michowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maya Koren‐Michowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maya Koren‐Michowitz. The network helps show where Maya Koren‐Michowitz may publish in the future.

Co-authorship network of co-authors of Maya Koren‐Michowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Maya Koren‐Michowitz. A scholar is included among the top collaborators of Maya Koren‐Michowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maya Koren‐Michowitz. Maya Koren‐Michowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Margalit, Sapir, Yael Michaeli, Dmitry Torchinsky, et al.. (2023). Chemo‐Enzymatic Fluorescence Labeling Of Genomic DNA For Simultaneous Detection Of Global 5‐Methylcytosine And 5‐Hydroxymethylcytosine**. ChemBioChem. 24(20). e202300400–e202300400. 7 indexed citations

Blickstein, Dorit, Marina Izak, Naomi Rahimi‐Levene, et al.. (2023). Antiphospholipid antibodies in convalescent plasma of donors recovered from mild COVID‐19 infection. Vox Sanguinis. 118(7). 517–522. 1 indexed citations

Gutwein, Odit, et al.. (2023). Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study. Cancer Medicine. 12(21). 20503–20510. 2 indexed citations

Gutwein, Odit, et al.. (2021). BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies. American Journal of Hematology. 96(10). 1195–1203. 106 indexed citations

Rahimi‐Levene, Naomi, et al.. (2021). Hematological Biomarkers, Mortality, Transfusion and Acute Heart Disease. The American Journal of the Medical Sciences. 362(3). 276–284. 2 indexed citations

Ganzel, Chezi, Ron Ram, Alexander Gural, et al.. (2020). Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia & lymphoma. 61(9). 2221–2225. 30 indexed citations

Apel, Arie, Yishai Ofran, Ofir Wolach, et al.. (2020). Safety and efficacy of blinatumomab: a real world data. Annals of Hematology. 99(4). 835–838. 21 indexed citations

Hauschner, Hagit, et al.. (2019). Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets. American Journal of Hematology. 95(4). 379–386. 17 indexed citations

Yassin, Muhammad, Peter van Galen, B Bernstein, et al.. (2019). A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity. Leukemia. 33(8). 2061–2077. 10 indexed citations

10.

Michowitz, Yoav, Robert Klempfner, Shlomo Nir, Ilan Goldenberg, & Maya Koren‐Michowitz. (2019). Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy. PLoS ONE. 14(11). e0224709–e0224709. 4 indexed citations

11.

Zuckerman, Tsila, Ron Ram, Luiza Akria, et al.. (2019). BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. Blood Advances. 3(22). 3740–3749. 10 indexed citations

12.

Rahimi‐Levene, Naomi, Tomer Ziv‐Baran, Victoria Peer, et al.. (2018). Hemoglobin transfusion trigger in an internal medicine department – A "real world" six year experience. PLoS ONE. 13(3). e0193873–e0193873. 12 indexed citations

13.

Beider, Katia, Avichai Shimoni, Merav Leiba, et al.. (2016). The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. Clinical Cancer Research. 23(7). 1733–1747. 33 indexed citations

14.

Koren‐Michowitz, Maya, Noa Lavi, Martin Ellis, et al.. (2016). Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. Annals of Hematology. 96(1). 87–92. 15 indexed citations

15.

Ellis, Martin, Noa Lavi, Elena Mishchenko, et al.. (2015). Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice. Leukemia Research. 39(11). 1154–1158. 7 indexed citations

16.

Koren‐Michowitz, Maya, Avichai Shimoni, Yulia Volchek, et al.. (2015). Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post–Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation. 21(10). 1852–1855. 2 indexed citations

17.

Beider, Katia, Merav Darash‐Yahana, Maya Koren‐Michowitz, et al.. (2014). Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo. Molecular Cancer Therapeutics. 13(5). 1155–1169. 51 indexed citations

18.

Koren‐Michowitz, Maya, Aiko Sato‐Otsubo, Arnon Nagler, et al.. (2011). Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis. Leukemia Research. 36(4). 467–473. 6 indexed citations

19.

Trakhtenbrot, Luba, Izhar Hardan, Maya Koren‐Michowitz, et al.. (2009). Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma. Genes Chromosomes and Cancer. 49(1). 17–27. 17 indexed citations

20.

Koren‐Michowitz, Maya, et al.. (2005). Coinheritance ofBRCA1 andBRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: Possible role in risk modification for cancer development. American Journal of Hematology. 78(3). 203–206. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact